Platelet activating factor inhibition reduces lung injury after cardiopulmonary bypass

Kenton J Zehr, Robert S. Poston, Paul C. Lee, Kay Uthoff, Pankaj Kumar, Peter W. Cho, A. Marc Gillinov, J. Mark Redmond, Jerry A. Winkelstein, Ahvie Herskowitz, Duke E. Cameron

Research output: Contribution to journalArticle

Abstract

Because cardiopulmonary bypass (CPB) produces a diffuse inflammatory reaction that may injure multiple organs and complicate cardiac surgical procedures, we examined the use of a competitive inhibitor of platelet activating factor (SDZ HUL-412) in a porcine model of CPB as a means to ameliorate pulmonary injury after CPB. Thirteen pigs (35 to 40 kg) underwent CPB at 28°C for 2 hours, followed by 2 hours of observation. Group I (n = 6) received SDZ HUL-412 (a quinolinium compound) intravenously (3 mg/kg loading dose and 2 mg · kg-1 · h-1 continuous infusion) starting before sternotomy. Group II (n = 7) received a saline vehicle. Peak airway pressure, pulmonary arterial pressure, left atrial pressure, and arterial blood gases were measured and flow cytometry evaluated surface expression of adhesion molecule subunit CD18 on circulating neutrophils. Pulmonary function was significantly improved in group I. Fifteen minutes after CPB, dynamic lung compliance in group I was 91% ± 12% of baseline versus 49% ± 5.2% in group II (p = 0.06 by analysis of variance). After CPB, the arterial oxygen pressure was also significantly better in group I than in group II (425 ± 61 versus 234 ± 76 mm Hg) (p <0.05). The rise in pulmonary vascular resistance after CPB was less in group I (p <0.05) (323 ± 55 to 553 ± 106 dynes · s · cm-5) than in group II (531 ± 177 to 884 ± 419 dynes · s · cm-5) at the end of the observation period. CD18 up-regulation increased similarly in the two groups during CPB. Histologic evaluation revealed normal pulmonary architecture in group I, but group II had marked intraalveolar hemorrhage, abundant neutrophils, and edema fluid. Significant edema was present in group I fields (41.0% ± 11.7%) versus group II fields (5.05% ± 1.5%) (p <0.02). This study demonstrates that platelet activating factor inhibition during CPB (1) decreases pulmonary vascular resistance after CPB, (2) increases the arterial oxygen pressure, and (3) decreases histologic lung damage, but (4) has no effect on surface expression of CD18. Platelet activating factor inhibition may have clinical applicability in the amelioration of organ damage after CPB.

Original languageEnglish (US)
Pages (from-to)328-335
Number of pages8
JournalAnnals of Thoracic Surgery
Volume59
Issue number2
DOIs
StatePublished - 1995

Fingerprint

Platelet Activating Factor
Lung Injury
Cardiopulmonary Bypass
Lung
Arterial Pressure
Quinolinium Compounds
Vascular Resistance
Edema
Neutrophils
Swine
Cardiac Surgical Procedures
Observation
Oxygen
Lung Compliance
Atrial Pressure
Sternotomy
Analysis of Variance
Flow Cytometry
Up-Regulation
Gases

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Zehr, K. J., Poston, R. S., Lee, P. C., Uthoff, K., Kumar, P., Cho, P. W., ... Cameron, D. E. (1995). Platelet activating factor inhibition reduces lung injury after cardiopulmonary bypass. Annals of Thoracic Surgery, 59(2), 328-335. https://doi.org/10.1016/0003-4975(94)00725-M

Platelet activating factor inhibition reduces lung injury after cardiopulmonary bypass. / Zehr, Kenton J; Poston, Robert S.; Lee, Paul C.; Uthoff, Kay; Kumar, Pankaj; Cho, Peter W.; Gillinov, A. Marc; Redmond, J. Mark; Winkelstein, Jerry A.; Herskowitz, Ahvie; Cameron, Duke E.

In: Annals of Thoracic Surgery, Vol. 59, No. 2, 1995, p. 328-335.

Research output: Contribution to journalArticle

Zehr, KJ, Poston, RS, Lee, PC, Uthoff, K, Kumar, P, Cho, PW, Gillinov, AM, Redmond, JM, Winkelstein, JA, Herskowitz, A & Cameron, DE 1995, 'Platelet activating factor inhibition reduces lung injury after cardiopulmonary bypass', Annals of Thoracic Surgery, vol. 59, no. 2, pp. 328-335. https://doi.org/10.1016/0003-4975(94)00725-M
Zehr, Kenton J ; Poston, Robert S. ; Lee, Paul C. ; Uthoff, Kay ; Kumar, Pankaj ; Cho, Peter W. ; Gillinov, A. Marc ; Redmond, J. Mark ; Winkelstein, Jerry A. ; Herskowitz, Ahvie ; Cameron, Duke E. / Platelet activating factor inhibition reduces lung injury after cardiopulmonary bypass. In: Annals of Thoracic Surgery. 1995 ; Vol. 59, No. 2. pp. 328-335.
@article{b180b30d452e4359bbace87d25a4231e,
title = "Platelet activating factor inhibition reduces lung injury after cardiopulmonary bypass",
abstract = "Because cardiopulmonary bypass (CPB) produces a diffuse inflammatory reaction that may injure multiple organs and complicate cardiac surgical procedures, we examined the use of a competitive inhibitor of platelet activating factor (SDZ HUL-412) in a porcine model of CPB as a means to ameliorate pulmonary injury after CPB. Thirteen pigs (35 to 40 kg) underwent CPB at 28°C for 2 hours, followed by 2 hours of observation. Group I (n = 6) received SDZ HUL-412 (a quinolinium compound) intravenously (3 mg/kg loading dose and 2 mg · kg-1 · h-1 continuous infusion) starting before sternotomy. Group II (n = 7) received a saline vehicle. Peak airway pressure, pulmonary arterial pressure, left atrial pressure, and arterial blood gases were measured and flow cytometry evaluated surface expression of adhesion molecule subunit CD18 on circulating neutrophils. Pulmonary function was significantly improved in group I. Fifteen minutes after CPB, dynamic lung compliance in group I was 91{\%} ± 12{\%} of baseline versus 49{\%} ± 5.2{\%} in group II (p = 0.06 by analysis of variance). After CPB, the arterial oxygen pressure was also significantly better in group I than in group II (425 ± 61 versus 234 ± 76 mm Hg) (p <0.05). The rise in pulmonary vascular resistance after CPB was less in group I (p <0.05) (323 ± 55 to 553 ± 106 dynes · s · cm-5) than in group II (531 ± 177 to 884 ± 419 dynes · s · cm-5) at the end of the observation period. CD18 up-regulation increased similarly in the two groups during CPB. Histologic evaluation revealed normal pulmonary architecture in group I, but group II had marked intraalveolar hemorrhage, abundant neutrophils, and edema fluid. Significant edema was present in group I fields (41.0{\%} ± 11.7{\%}) versus group II fields (5.05{\%} ± 1.5{\%}) (p <0.02). This study demonstrates that platelet activating factor inhibition during CPB (1) decreases pulmonary vascular resistance after CPB, (2) increases the arterial oxygen pressure, and (3) decreases histologic lung damage, but (4) has no effect on surface expression of CD18. Platelet activating factor inhibition may have clinical applicability in the amelioration of organ damage after CPB.",
author = "Zehr, {Kenton J} and Poston, {Robert S.} and Lee, {Paul C.} and Kay Uthoff and Pankaj Kumar and Cho, {Peter W.} and Gillinov, {A. Marc} and Redmond, {J. Mark} and Winkelstein, {Jerry A.} and Ahvie Herskowitz and Cameron, {Duke E.}",
year = "1995",
doi = "10.1016/0003-4975(94)00725-M",
language = "English (US)",
volume = "59",
pages = "328--335",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Platelet activating factor inhibition reduces lung injury after cardiopulmonary bypass

AU - Zehr, Kenton J

AU - Poston, Robert S.

AU - Lee, Paul C.

AU - Uthoff, Kay

AU - Kumar, Pankaj

AU - Cho, Peter W.

AU - Gillinov, A. Marc

AU - Redmond, J. Mark

AU - Winkelstein, Jerry A.

AU - Herskowitz, Ahvie

AU - Cameron, Duke E.

PY - 1995

Y1 - 1995

N2 - Because cardiopulmonary bypass (CPB) produces a diffuse inflammatory reaction that may injure multiple organs and complicate cardiac surgical procedures, we examined the use of a competitive inhibitor of platelet activating factor (SDZ HUL-412) in a porcine model of CPB as a means to ameliorate pulmonary injury after CPB. Thirteen pigs (35 to 40 kg) underwent CPB at 28°C for 2 hours, followed by 2 hours of observation. Group I (n = 6) received SDZ HUL-412 (a quinolinium compound) intravenously (3 mg/kg loading dose and 2 mg · kg-1 · h-1 continuous infusion) starting before sternotomy. Group II (n = 7) received a saline vehicle. Peak airway pressure, pulmonary arterial pressure, left atrial pressure, and arterial blood gases were measured and flow cytometry evaluated surface expression of adhesion molecule subunit CD18 on circulating neutrophils. Pulmonary function was significantly improved in group I. Fifteen minutes after CPB, dynamic lung compliance in group I was 91% ± 12% of baseline versus 49% ± 5.2% in group II (p = 0.06 by analysis of variance). After CPB, the arterial oxygen pressure was also significantly better in group I than in group II (425 ± 61 versus 234 ± 76 mm Hg) (p <0.05). The rise in pulmonary vascular resistance after CPB was less in group I (p <0.05) (323 ± 55 to 553 ± 106 dynes · s · cm-5) than in group II (531 ± 177 to 884 ± 419 dynes · s · cm-5) at the end of the observation period. CD18 up-regulation increased similarly in the two groups during CPB. Histologic evaluation revealed normal pulmonary architecture in group I, but group II had marked intraalveolar hemorrhage, abundant neutrophils, and edema fluid. Significant edema was present in group I fields (41.0% ± 11.7%) versus group II fields (5.05% ± 1.5%) (p <0.02). This study demonstrates that platelet activating factor inhibition during CPB (1) decreases pulmonary vascular resistance after CPB, (2) increases the arterial oxygen pressure, and (3) decreases histologic lung damage, but (4) has no effect on surface expression of CD18. Platelet activating factor inhibition may have clinical applicability in the amelioration of organ damage after CPB.

AB - Because cardiopulmonary bypass (CPB) produces a diffuse inflammatory reaction that may injure multiple organs and complicate cardiac surgical procedures, we examined the use of a competitive inhibitor of platelet activating factor (SDZ HUL-412) in a porcine model of CPB as a means to ameliorate pulmonary injury after CPB. Thirteen pigs (35 to 40 kg) underwent CPB at 28°C for 2 hours, followed by 2 hours of observation. Group I (n = 6) received SDZ HUL-412 (a quinolinium compound) intravenously (3 mg/kg loading dose and 2 mg · kg-1 · h-1 continuous infusion) starting before sternotomy. Group II (n = 7) received a saline vehicle. Peak airway pressure, pulmonary arterial pressure, left atrial pressure, and arterial blood gases were measured and flow cytometry evaluated surface expression of adhesion molecule subunit CD18 on circulating neutrophils. Pulmonary function was significantly improved in group I. Fifteen minutes after CPB, dynamic lung compliance in group I was 91% ± 12% of baseline versus 49% ± 5.2% in group II (p = 0.06 by analysis of variance). After CPB, the arterial oxygen pressure was also significantly better in group I than in group II (425 ± 61 versus 234 ± 76 mm Hg) (p <0.05). The rise in pulmonary vascular resistance after CPB was less in group I (p <0.05) (323 ± 55 to 553 ± 106 dynes · s · cm-5) than in group II (531 ± 177 to 884 ± 419 dynes · s · cm-5) at the end of the observation period. CD18 up-regulation increased similarly in the two groups during CPB. Histologic evaluation revealed normal pulmonary architecture in group I, but group II had marked intraalveolar hemorrhage, abundant neutrophils, and edema fluid. Significant edema was present in group I fields (41.0% ± 11.7%) versus group II fields (5.05% ± 1.5%) (p <0.02). This study demonstrates that platelet activating factor inhibition during CPB (1) decreases pulmonary vascular resistance after CPB, (2) increases the arterial oxygen pressure, and (3) decreases histologic lung damage, but (4) has no effect on surface expression of CD18. Platelet activating factor inhibition may have clinical applicability in the amelioration of organ damage after CPB.

UR - http://www.scopus.com/inward/record.url?scp=0028869591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028869591&partnerID=8YFLogxK

U2 - 10.1016/0003-4975(94)00725-M

DO - 10.1016/0003-4975(94)00725-M

M3 - Article

VL - 59

SP - 328

EP - 335

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 2

ER -